LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial
LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial
To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).
Inclusion Criteria:
Exclusion Criteria:
- Inability or unwillingness to take folic acid or vitamin B12 supplementation
Chiba, Japan
Ehime, Japan
Fukuoka, Japan
Gifu, Japan
Gunma, Japan
Hokkaido, Japan
Hyōgo, Japan
Kanagawa, Japan
Kumamoto, Japan
Miyagi, Japan
Niigata, Japan
Okayama, Japan
Osaka, Japan
Saitama, Japan
Shizuoka, Japan